• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans

* * * * * 1 votes

Canagliflozin extends lifespan in genetically heterogeneous male but not female mice

canagliflozin aspirin rapamycin acarbose protandim 17-α-estradiol nordihydroguaiaretic acid (ndga) aging life extensionm lifespan

  • Please log in to reply
No replies to this topic


  • Member
  • 863 posts
  • 356

Posted 04 October 2020 - 01:32 PM

FULL TEXT:  https://insight.jci....view/140019/pdf




Canagliflozin extends lifespan in genetically heterogeneous male but not female mice Richard A. Miller,1 David E. Harrison,2 David B. Allison,3 Molly A. Bogue,2 Lucas K. Debarba,4 Vivian Diaz,5 Elizabeth Fernandez,5 Andrzej T. Galecki,6 W. Timothy Garvey,7 Hashan Jayarathne,8 Navasuja Kumar,9 Martin Javors,10 Warren Ladiges,11 Francesca Macchiarini,12 James F. Nelson,13 Peter C. Reifsnyder,14 Nadia Rosenthal,14 Marianna Sadagurski,4 Adam B. Salmon,13 Daniel L. Smith, Jr.,15 Jessica M. Snyder,11 David B. Lombard,16 and Randy Strong5

First published September 29, 2020 - More info


Canagliflozin (Cana) is an inhibitor of the sodium glucose transporter 2 (SGLT2), and is thought to act by blocking renal reuptake and intestinal absorption of glucose. Cana is FDA-approved for treatment of diabetes, and affords protection from cardiovascular and kidney diseases. In the context of the mouse Interventions Testing Program, genetically heterogeneous mice were given chow containing 180 ppm Cana at 7 months of age until their death. Cana extended median survival of male mice by 14%, with p < 0.001 by log-rank test. Cana also increased by 9% the age for 90th percentile survival (p < 0.001 by Wang/Allison test), with parallel effects seen at each of three test sites. Cana did not alter the distribution of inferred cause of death, nor of incidental pathology findings at end-of-life necropsies. No benefits were seen in female mice. The lifespan benefit of Cana is likely to reflect blunting of peak glucose levels, because similar longevity effects are seen in mice given acarbose, a diabetes drug that blocks glucose surges through a distinct mechanism, i.e. slowing breakdown of carbohydrate in the intestine. Interventions that control daily peak glucose levels deserve attention as possible preventive medicines to protect from a wide range of late-life neoplastic and degenerative diseases.

Graphical Abstract
Supplemental material
 Version history
  • Version 1 (September 29, 2020): In-Press Preview


Edited by APBT, 04 October 2020 - 01:47 PM.

Also tagged with one or more of these keywords: canagliflozin, aspirin, rapamycin, acarbose, protandim, 17-α-estradiol, nordihydroguaiaretic acid (ndga), aging, life extensionm, lifespan

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users